Uganda expands PrEP options in combating HIV Using Media

Journalists in Kampala gathered for a media orientation on HIV and PrEP updates, where they received the latest information on Uganda’s ongoing efforts to combat the HIV epidemic.

Despite a 63% decline in AIDS-related deaths as of 2023, Uganda continues to record 730 new HIV cases each week, with young girls aged 15-24 accounting for 80% of these infections. It is estimated that 150,000 young people are living with HIV.

Dr. Herbert Kadama, manager of PrEP at the Ministry of Health, announced the availability of multiple pre-exposure prophylaxis (PrEP) options for individuals at substantial risk of acquiring HIV. These options include a daily oral pill, an event-driven dosing option for HIV-negative males, a dapivirine vaginal ring replaced every 28 days, a long-acting injectable cabotegravir administered every two months, and Lenacapavir, a twice-yearly injectable.

According to UNAIDS, Uganda’s HIV prevalence rate currently stands at 5.5% among adults aged 15-49 years, with an estimated 38,000 new infections reported in 2023.

Dr. Diana Atwine, Permanent Secretary of the Ministry of Health, emphasised the ministry’s commitment to supporting PrEP options, even though they are not yet available in many health facilities. “We will support PrEP technologies 100%,” she stated. However, she also urged the public not to rely solely on PrEP, reminding them that these are supplementary options meant for specific circumstances.

PrEP is currently available at several health facilities, including Mbarara Municipal Health Centre IV, Bufunda Health Centre III, Kitgum Hospital, Gulu Regional Referral Hospital, Namakwekwe Health Centre III, Bison Health Centre III, and Malaba Health Centre IV.

Dr. Flavia Matovu, Head of Research at MUJHU, highlighted the potential of Lenacapavir in disrupting multiple stages of the HIV viral lifecycle, noting its 100% efficacy in preventing HIV infection during clinical trials. The Ministry of Health will support at-risk populations in accessing these PrEP options but emphasises the need for continued vigilance, as PrEP is not a substitute for condoms or other prevention methods.

Globally, significant advancements have been made in HIV prevention, and the Ministry of Health is committed to integrating these innovations into the country’s National HIV Combination Prevention Strategy. Lenacapavir, an injectable PrEP currently under review, has shown 100% efficacy in preventing HIV transmission among women and adolescent girls in the PURPOSE 1 trial, led by Gilead Sciences.

The ministry emphasises the importance of comprehensive prevention strategies, including testing, awareness campaigns, condom distribution, and safe male circumcision.